Clinical Trials for Recurrent Acute Lymphoblastic Leukemia

Find clinical trials for recurrent acute lymphoblastic leukemia. Discover research opportunities and treatment options in your area.

10 Active Trials Found

Showing 10 trials on this page

Page 1 of 1

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

NCT ID: NCT03326921

This clinical trial is testing a new type of immunotherapy called HA-1 T cell therapy to treat patients with certain types of acute leukemia that have come back, are not responding to treatment, or...

Recruiting

Phase: PHASE1 Type: interventional Locations: Seattle, Washington, United States

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

NCT ID: NCT03128034

This clinical trial is looking at a new treatment called 211^astatine-BC8-B10 for patients with certain types of blood cancers, including high-risk acute myeloid leukemia (AML), acute lymphoblastic...

Recruiting

Phase: PHASE1 Type: interventional Locations: Seattle, Washington, United States

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

NCT ID: NCT05761171

This clinical trial is exploring a new treatment for young children with certain types of leukemia that have either come back after previous treatment (relapsed) or did not respond to treatment (re...

Recruiting

Phase: PHASE2 Type: interventional Locations: Philadelphia, Pennsylvania, United States, Buffalo, New York, United States +83 more

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

NCT ID: NCT03263572

This clinical trial is studying a combination of four medications—blinatumomab, methotrexate, cytarabine, and ponatinib—to see how well they work for patients with Philadelphia chromosome-positive ...

Recruiting

Phase: PHASE2 Type: interventional Locations: Houston, Texas, United States

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

NCT ID: NCT03670966

This clinical trial is studying a new treatment approach for patients with high-risk acute leukemia or myelodysplastic syndrome, especially those whose disease has come back or is not responding to...

Recruiting

Phase: PHASE1 Type: interventional Locations: Seattle, Washington, United States

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

NCT ID: NCT05418088

This clinical trial is studying a new treatment for certain types of blood cancers, specifically targeting those that have come back or have not responded to previous treatments. The treatment invo...

Recruiting

Phase: PHASE1 Type: interventional Locations: Columbus, Ohio, United States, Columbus, Ohio, United States

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

NCT ID: NCT02392572

This clinical trial is studying a new treatment called ONC201 for patients with certain types of leukemia or high-risk myelodysplastic syndrome (a blood disorder) that have either returned after tr...

Recruiting

Phase: PHASE1 Type: interventional Locations: Houston, Texas, United States

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

NCT ID: NCT03136146

This clinical trial is studying a combination of chemotherapy drugs to see how well they work for patients with certain types of blood cancers, including acute lymphoblastic leukemia (ALL), lymphob...

Recruiting

Phase: PHASE2 Type: interventional Locations: Houston, Texas, United States

CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

NCT ID: NCT06777979

This clinical trial is studying a new treatment called CD19-CD22-Bispecific CAR T Cell Therapy for children and young adults up to 21 years old who have certain types of leukemia, specifically Acut...

Recruiting

Phase: PHASE1 Type: interventional Locations: Memphis, Tennessee, United States

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

NCT ID: NCT06447987

This clinical trial is studying a new treatment called CAR T-cell therapy for adults with a type of blood cancer known as CD19 positive B-cell acute lymphoblastic leukemia (ALL) that has either ret...

Recruiting

Phase: PHASE1 Type: interventional Locations: Duarte, California, United States

Related Conditions

Breast Cancer View clinical trials → Stroke View clinical trials → Obesity View clinical trials → Cancer View clinical trials → Healthy View clinical trials → Prostate Cancer View clinical trials →

Search All Trials Browse All Conditions